Article citationsMore>>

Vergote, I., Dean, E., Lassen, U., de Bono, J., Drew, Y., Machiels, J.-P., Nielsen, D., Arkenau, H.-T., Forster, M., Jones, R., Slomovitz, B., Spicer, J., Johnson, M., Cornez, N., Gennigens, C., Fulton, B., Lisby, S., Basse, L., Coleman, R. and Hong, D.S. (2017) A Phase IIa Study of Tisotumab Vedotin (HuMax®-TF-ADC) in Patients with Relapsed, Recurrent and/or Metastatic Cervical Cancer. Annals of Oncology, 28, V330-V331. https://doi.org/10.1093/annonc/mdx372.001

has been cited by the following article:

• TITLE: Biotechnology Application of Therapeutic Antibody Drug Discovery and Preparation

  AUTHORS: Huilin Cao

  KEYWORDS: Therapeutic Monoclonal Antibodies, Antibody Engineering, Targeted, ADC

  JOURNAL NAME: Open Access Library Journal, Vol.8 No.8, July 29, 2021

  ABSTRACT: According to the technical application, therapeutic mechanism and application prospect of therapeutic antibodies are discussed from the research and development of therapeutic antibodies to their application technology. Also, following is a list of some disadvantages of the drug. May this article shall lead perspective in the next section.